David Stover
16Patents
5h-index
23Co-inventors
66Inventor score
Filing activity: Oct 20, 1999 → Sep 14, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6258812A | Phthalazines with angiogenesis inhibiting activity | Chemistry; Metallurgy | 50 | Expired |
| US8101727B2 | Compositions and methods of use for antibodies of c-Met | Emerging Cross-Sectional Technologies | 25 | Active |
| US6710047B2 | Phthalazines with angiogenesis inhibiting activity | Chemistry; Metallurgy | 14 | Expired |
| US6514974B2 | Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity | Chemistry; Metallurgy | 7 | Expired |
| US9120855B2 | Biologic compounds directed against death receptor 5 | Chemistry; Metallurgy | 6 | Active |
| US11136353B2 | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 2 | Active |
| US12311010B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11833209B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | Human Necessities | 0 | Active |
| US11795198B2 | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 0 | Active |
| US12162958B2 | Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 0 | Active |
| US11801304B2 | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof | Human Necessities | 0 | Active |
| US11744874B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12059470B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | Human Necessities | 0 | Active |
| US11896646B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11679141B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12286403B2 | Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.